ERBB2 and breast carcinoma: Breast cancer cell lines proved useful in laboratory and preclinical investigations and accurately predicted outcomes for endocrine or anti-HER2 therapeutics in clinical trials, particularly for hormone-responsive or HER2-overexpressed cancer subtypes, respectively.